Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa‐carbidopa intestinal gel infusion vs. oral tablets
Authors:
Open Access
- 20 June 2014
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 78 (1) , 94-105
Abstract
Aims: Levodopa‐carbidopa intestinal gel (LCIG) provides continuous levodopa‐carbidopa delivery through intrajejunal infusion. This study characterized the population pharmacokinetics of levodopa following a 16 h jejunal infusion of LCIG or frequent oral administration of levodopa‐carbidopa tablets (LC‐oral) in subjects with advanced Parkinson's disease (PD).Methods: A non‐linear mixed‐effects model of levodopa pharmacokinetics was developed using serial plasma concentrations from an LCIG phase 1 study and a phase 3 double‐blind, double‐dummy study of the efficacy and safety of LCIG compared with LC‐oral in advanced PD patients (n = 68 for model development; 45 on LCIG and 23 on LC‐oral). The final model was internally evaluated using stochastic simulations and bootstrap and externally evaluated using sparse pharmacokinetic data from 311 subjects treated in a long term safety study of LCIG.Results: The final model was a two compartment model with a transit compartment for absorption, first order elimination, bioavailability for LCIG (97%; confidence interval = 95% to 98%) relative to LC‐oral, different first order transit absorption rate constants (LCIG = 9.2 h–1 vs. LC‐oral = 2.4 h–1; corresponding mean absorption time of 7 min for LCIG vs. 25 min for LC‐oral) and different residual (intra‐subject) variability for LCIG (15% proportional error, 0.3 μg ml−1 additive error) vs. LC‐oral (29% proportional error, 0.59 μg ml−1 additive error). Estimated oral clearance and steady‐state volume of distribution for levodopa were 24.8 l h−1 and 131 l, respectively.Conclusions: LCIG administration results in faster absorption, comparable levodopa bioavailability and significantly reduced intra‐subject variability in levodopa concentrations relative to LC‐oral administration.Keywords
Funding Information
- AbbVie
This publication has 28 references indexed in Scilit:
- Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim resultsParkinsonism & Related Disorders, 2013
- A Pharmacokinetic-Pharmacodynamic Model for Duodenal Levodopa InfusionClinical Neuropharmacology, 2011
- Prediction-Corrected Visual Predictive Checks for Diagnosing Nonlinear Mixed-Effects ModelsThe AAPS Journal, 2011
- Importance of Shrinkage in Empirical Bayes Estimates for Diagnostics: Problems and SolutionsThe AAPS Journal, 2009
- How do you treat motor complications in Parkinson's disease: Medicine, surgery, or both?Annals of Neurology, 2009
- Pharmacokinetics and pharmacodynamics of levodopaMovement Disorders, 2008
- Basic Research on Dopamine in Parkinson’s Disease and the Discovery of the Nigrostriatal Dopamine Pathway: The View of an EyewitnessNeurodegenerative Diseases, 2008
- Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?Neurological Sciences, 2003
- Optimizing Levodopa Pharmacokinetics: Intestinal Infusion Versus Oral Sustained-Release TabletsClinical Neuropharmacology, 2003
- Idiopathic Parkinsonism Treated with an Extracerebral Decarboxylase Inhibitor in Combination with LevodopaBMJ, 1971